Details:

Alternative Title:
Clin Infect Dis
Personal Author:
Ershova, Julia V. ; Kurbatova, Ekaterina V. ; Moonan, Patrick K. ; Cegielski, J. Peter
Ershova, Julia V. ; Kurbatova, Ekaterina V. ; Moonan, Patrick K. ; Cegielski, J. Peter Less -
Description:
Background

Resistance to second-line anti-tuberculosis drugs (SLD) severely compromises treatment options of drug-resistant tuberculosis (TB). We assessed the association between acquisition of resistance (AR) to second-line injectable drugs (SLI) or fluoroquinolones (FQ) and mortality among TB cases confirmed by positive culture results with available initial and final drug susceptibility test (DST) results.

Methods

We analyzed data from U.S. National TB Surveillance System, 1993–2008. Acquired resistance was defined as drug susceptibility at initial DST but resistance to the same drug at final DST. We compared survival with Kaplan-Meier curves and analyzed the association between AR and mortality using a univariate extended Cox proportional hazards model adjusted for age.

Results

Of 2,329 cases with both initial and final DST to SLI, 49 (2.1%) acquired resistance; 13/49 (26.5%) had treatment terminated by death versus 222 (10.0%) of those without AR to SLI (P<0.001). Of 1,187 cases with both initial and final DST to FQ, 32 (2.8%) acquired resistance; 12/32 (37.5%) had treatment terminated by death versus 121 (10.9%) of those without AR to FQ (P=0.001). Controlling for age, mortality was significantly greater among cases with AR to SLD than among cases without AR (adjusted hazard ratio (aHR)[SLI], 2.8; 95% confidence interval (CI),1.4–5.4; aHR[FQ], 1.9; 95% CI,1.0–3.5). MDR TB at treatment initiation, positive HIV status, and extrapulmonary disease were also significantly associated with mortality.

Conclusion

Mortality was significantly greater among TB cases with AR to SLD. Providers should consider AR to SLD early in treatment, monitor DST results, and avoid premature deaths.


Subjects:
[+]
Adult Aged Antitubercular Agents Drug Resistance, Bacterial Female HIV Humans Male Middle Aged Mycobacterium Tuberculosis Survival Analysis Tuberculosis, Multidrug-Resistant
Source:
Clin Infect Dis. 59(4):465-472
Pubmed ID:
24846639
Pubmed Central ID:
PMC4784225
Document Type:
Journal Article
Funding:
CC999999/Intramural CDC HHS/United States
Place as Subject:
United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:86ac53df94adc4b069f29b2901198a3cb96611938d8f3ed53f1f731f7aedf0bf
Download URL:
https://stacks.cdc.gov/view/cdc/38399/cdc_38399_DS1.pdf
File Type:

Supporting Files

• 	nihms761579f2.jpg	jpeg
  	nihms761579f3.gif	gif
  	nihms761579f3.jpg	jpeg
  	nihms761579.nxml	xml
  	nihms761579f1a.gif	gif
  	nihms761579f1a.jpg	jpeg
  	nihms761579f1b.gif	gif
  	nihms761579f1b.jpg	jpeg
  	nihms761579f1c.gif	gif
  	nihms761579f1c.jpg	jpeg
  	nihms761579f2.gif	gif

More +